Sanofi may win U.S. approval of $3 bln eczema drug by March
September 26, 2016 at 03:24 AM EDT
Sept 26 (Reuters) - French drugmaker Sanofi and its U.S. partner Regeneron Pharmaceuticals could win U.S. approval for their keenly awaited new eczema drug dupilumab, seen by analysts as a potential $3 billion-a-year seller, by next March.
